Syntax Bio’s technology platform uses CRISPR to direct stem cells to become a desired cell type in a process that’s more scalable and less expensive than current methods. The startup is raising a Series A round of financing to further demonstrate the potential of its technology.
The post Startup Syntax Bio Leverages CRISPR to Transform Cell Therapy Manufacturing appeared first on Above the Law.
[I will blog the NetChoice v. Bonta ruling very soon.] Many state legislatures draft Internet regulations without any genuine concern for whether or not the…
[This guest post is by Maya Markovich, executive director of the Justice Technology Association, an organization formed to support companies in the justice tech sector.…
Casgevy, from Vertex Pharmaceuticals and CRISPR Therapeutics, is now approved in the United Kingdom for treating the blood disorders sickle cell disease and beta thalassemia.…
Thomson Reuters today delivered on its promise to integrate generative AI within its flagship legal research platform, introducing AI Assisted Research in Westlaw Precision, available…
With the launch today of its second-generation platform, London-based Legatics is expanding the capabilities it offers customers from its core of legal transaction management into…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
Responses